Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study

G.J. Schmieder; Z.D. Draelos; D.M. Pariser; C. Banfield; L. Cox; M. Hodge; E. Kieras; D. Parsons-Rich; S. Menon; M. Salganik; K. Page; E. Peeva

doi:10.1111/bjd.16004

Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study

British Journal of Dermatology ◽

10.1111/bjd.16004 ◽

2018 ◽

Vol 179 (1) ◽

pp. 54-62 ◽

Cited By ~ 27

Author(s):

G.J. Schmieder ◽

Z.D. Draelos ◽

D.M. Pariser ◽

C. Banfield ◽

L. Cox ◽

...

Keyword(s):

Phase Ii ◽

Severe Psoriasis ◽

Janus Kinase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Janus Kinase 1

Download Full-text

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.12081 ◽

2013 ◽

Vol 28 (2) ◽

pp. 192-203 ◽

Cited By ~ 38

Author(s):

C. Mamolo ◽

J. Harness ◽

H. Tan ◽

A. Menter

Keyword(s):

Patient Reported Outcomes ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Controlled Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Patient Reported

Download Full-text

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese pediatric patients with atopic dermatitis: A phase II, randomized, double-blind, vehicle-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.224 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB53

Keyword(s):

Atopic Dermatitis ◽

Phase Ii ◽

Pediatric Patients ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

Arthritis & Rheumatism ◽

10.1002/art.34330 ◽

2012 ◽

Vol 64 (6) ◽

pp. 1730-1739 ◽

Cited By ~ 100

Author(s):

Michael Yellin ◽

Igor Paliienko ◽

Andra Balanescu ◽

Semen Ter-Vartanian ◽

Vira Tseluyko ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase Ii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725364136.793541451 ◽

2018 ◽

Author(s):

William Vainchenker ◽

Isabelle Plo

Keyword(s):

Dose Escalation ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Efficacy And Safety ◽

Dose Escalation Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo

Download Full-text

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis

British Journal of Dermatology ◽

10.1111/bjd.13745 ◽

2015 ◽

Vol 173 (3) ◽

pp. 767-776 ◽

Cited By ~ 53

Author(s):

K. Papp ◽

D. Pariser ◽

M. Catlin ◽

G. Wierz ◽

G. Ball ◽

...

Keyword(s):

Dose Escalation ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Efficacy And Safety ◽

Dose Escalation Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo

Download Full-text

Treating Anemia of Cancer with Every‐4‐Week Darbepoetin Alfa: Final Efficacy and Safety Results from a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study

The Oncologist ◽

10.1634/theoncologist.2007-0241 ◽

2008 ◽

Vol 13 (6) ◽

pp. 715-724 ◽

Cited By ~ 15

Author(s):

David Gordon ◽

Gwen Nichols ◽

Ali Ben‐Jacob ◽

Dianne Tomita ◽

Tom Lillie ◽

...

Keyword(s):

Phase Ii ◽

Darbepoetin Alfa ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Mo1540 THE EFFICACY AND SAFETY OF GCWB104 (FLOS LONICERA EXTRACT) IN FUNCTIONAL DYSPEPSIA: A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Gastroenterology ◽

10.1016/s0016-5085(20)32906-1 ◽

2020 ◽

Vol 158 (6) ◽

pp. S-887-S-888

Author(s):

Nayoung Kim ◽

Yonghoon Choi ◽

Dong Ho Lee

Keyword(s):

Functional Dyspepsia ◽

Controlled Study ◽

Efficacy And Safety ◽

Single Center ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Download Full-text

Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of AS-013, a Prostaglandin E1Prodrug, in Patients With Intermittent Claudication

Circulation ◽

10.1161/01.cir.95.9.2298 ◽

1997 ◽

Vol 95 (9) ◽

pp. 2298-2302 ◽

Cited By ~ 59

Author(s):

J.J.F. Belch ◽

P.R.F. Bell ◽

D. Creissen ◽

J.A. Dormandy ◽

R.C. Kester ◽

...

Keyword(s):

Intermittent Claudication ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study

Diabetologia ◽

10.1007/s00125-021-05460-0 ◽

2021 ◽

Author(s):

Linong Ji ◽

Ying Du ◽

Min Xu ◽

Xiangjun Zhou ◽

Zhaohui Mo ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Phase Ii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Treatment Naïve

Download Full-text